VIVEO (VVEO3) Main Indicators
Basic Data - VVEO3
| Company | VIVEO |
| Corporate Name | CM HOSPITALAR S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Distribuição e comércio atacadista de produtos para saúde. incluindo medicamentos. produtos médico-hospitalares e laboratoriais; vacinas para uso humano; dietas e leites nutricionais; cosméticos. |
| Share | VVEO3 |
| Quote Date | 09/18/2024 |
| Share Type | ON |
| Last Closing | R$ 2.35 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 6.06 M |
| Last Statement | ITR - 06/30/2024 |
| Sector | Saúde |
| Subsector | Comércio e Distribuição |
| Segment | Medicamentos e Outros Produtos |
| Participation Indexes | IBRA, ICON, IGC, IGCT, IGNM, ITAG, SMLL |
| Updated 09/19/2024 | |
Relative Prices - VVEO3
| Price/Earnings | 4.15 |
| Price/SBV | 0.23 |
| Price/Net Sales | 0.07 |
| Price/CFO | -2.78 |
| Price/FCF | -1.82 |
| Price/Total Assets | 0.07 |
| Price/EBIT | 1.95 |
| Price/Working Capital | 0.21 |
| Price/NCAV | -0.21 |
| EV/EBIT | 10.11 |
| EV/EBITDA | 5.86 |
| EV/Net Sales | 0.34 |
| EV/CFO | -14.46 |
| EV/FCF | -9.45 |
| EV/Total Assets | 0.37 |
| Company Market Cap | R$ 758.63 M |
| Enterprise Value | R$ 3.94 B |
| Current Financial Statement Date | 06/30/2024 |
| Current Share Price | R$ 2.35 |
| Share Price Date | 09/18/2024 |
| Dividend Yield | 5.81% |
| Updated 09/19/2024 | |
Income Statement - VVEO3
| Net Revenue | R$ 11.46 B |
| Gross Result | R$ 1.64 B |
| EBIT | R$ 389.90 M |
| Depreciation and Amortization | - R$ 282.40 M |
| EBITDA | R$ 672.30 M |
| Net Profit | R$ 182.88 M |
| Net Profit/Share | R$ 0.57 |
| Updated 08/12/2024 | |
| Net Revenue | R$ 2.75 B |
| Gross Result | R$ 397.28 M |
| EBIT | R$ 34.05 M |
| Depreciation and Amortization | - R$ 74.97 M |
| EBITDA | R$ 109.02 M |
| Net Profit | - R$ 87.72 M |
| Profit/Share | - R$ 0.27 |
| Updated 08/12/2024 | |
Price and Volume Behavior - VVEO3
| Lowest Price 52 weeks | R$ 1.85 |
| Highest Price 52 weeks | R$ 17.39 |
| Variation 2024 | -81.99% |
| Variation 1 year | -86.48% |
| Variation 2 years(total) | -85.74% |
| Variation 2 years(yearly) | -62.09% |
| Variation 3 years(total) | -89.84% |
| Variation 3 years(yearly) | -53.28% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 7.13 M |
| Updated 09/19/2024 | |
Returns and Margins - VVEO3
| Return on Initial Tangible Capital | 7.54% |
| Return on Initial Invested Capital | 5.11% |
| Pre-Tax Return on Initial Tangible Capital | 11.42% |
| Pre-Tax Return on Initial Invested Capital | 7.74% |
| Return on Initial Shareholder´s Equity | 7.70% |
| Return on Initial Asset | 2.03% |
| Gross Margin | 14.34% |
| Net Margin | 1.60% |
| EBIT Margin | 3.40% |
| EBITDA Margin | 5.87% |
| Initial Asset Turnover | 1.27 |
| Financial Leverage | 3.23 |
| Liabilities/Net Worth | 2.23 |
| Net Debt/EBITDA | 4.73 |
| Updated 08/12/2024 | |
Balance Sheet - VVEO3
| Cash and Cash Equivalents | R$ 720.73 M |
| Total Assets | R$ 10.53 B |
| Short-Term Debt | R$ 237.73 M |
| Long-Term Debt | R$ 3.67 B |
| Gross Debt | R$ 3.90 B |
| Net Debt | R$ 3.18 B |
| Shareholder´s Equity | R$ 3.26 B |
| Share Book Value | R$ 10.10 |
| Common Shares | 322,820,608 |
| Preferred Shares | 0 |
| Total | 322,820,608 |
| Common Shares in Treasury | 4,326,200 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 4,326,200 |
| Common Shares (Except Treasury) | 318,494,408 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 318,494,408 |
| Updated 08/12/2024 | |
Cash Flow - VVEO3
| Operating Cash Flow | - R$ 272.59 M |
| Cash Flow from Investments | - R$ 825.41 M |
| Financing Cash Flow | R$ 1.20 B |
| Increase (Reduction) in Cash and Equivalents | R$ 104.17 M |
| Updated 08/12/2024 | |
| Operating Cash Flow | R$ 259.50 M |
| Cash Flow from Investments | - R$ 274.21 M |
| Financing Cash Flow | - R$ 401.65 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 416.36 M |
| Updated 08/12/2024 | |
Experimental - VVEO3
| CAPEX 3 months | - R$ 18.54 M |
| Free Cash Flow 3 months | R$ 240.97 M |
| CAPEX 12 months | - R$ 144.22 M |
| Free Cash Flow 12 months | - R$ 416.81 M |
| Updated 08/12/2024 | |